{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Agios Pharmaceuticals, Inc.
Agios Pharmaceuticals Experiences Revision in Its Stock Evaluation Amid Market Dynamics
Agios Pharmaceuticals, Inc. has adjusted its valuation, showcasing a low P/E ratio of 4 and a price-to-book value of 1.73. Despite a challenging year, the company has demonstrated resilience with a year-to-date return of 28.82%, outperforming the S&P 500, and maintains a competitive PEG ratio of 0.01.
Is Agios Pharmaceuticals, Inc. overvalued or undervalued?
As of October 17, 2025, Agios Pharmaceuticals, Inc. is considered undervalued with a P/E ratio of 4 and a PEG ratio of 0.01, despite a recent shift in valuation grade from very attractive to attractive, and while it has outperformed the S&P 500 in the short term, its longer-term returns have lagged behind.
Is Agios Pharmaceuticals, Inc. overvalued or undervalued?
As of October 17, 2025, Agios Pharmaceuticals is considered an attractive investment due to its undervalued metrics, including a P/E ratio of 4 and a strong year-to-date return of 28.82%, despite a recent downgrade in valuation grade and long-term underperformance compared to the S&P 500.
Agios Pharmaceuticals Experiences Revision in Stock Evaluation Amid Market Dynamics
Agios Pharmaceuticals has recently revised its evaluation amid fluctuating market conditions. The stock, currently priced at $40.89, has shown significant volatility over the past year. Despite mixed short-term signals, Agios has outperformed the S&P 500 in various timeframes, reflecting its resilience and commitment to growth.
Is Agios Pharmaceuticals, Inc. technically bullish or bearish?
As of October 3, 2025, Agios Pharmaceuticals shows a bullish technical trend with strong momentum indicators, outperforming the S&P 500 in the short term, though it has underperformed over the long term.
Is Agios Pharmaceuticals, Inc. technically bullish or bearish?
As of October 3, 2025, Agios Pharmaceuticals shows a bullish technical trend with strong momentum indicators, despite mixed signals from KST and Dow Theory, and has outperformed the S&P 500 year-to-date.
Is Agios Pharmaceuticals, Inc. technically bullish or bearish?
As of October 3, 2025, Agios Pharmaceuticals shows a bullish technical trend with strong upward momentum indicated by MACD and RSI, despite some caution from mildly bearish KST and OBV signals.
Agios Pharmaceuticals Hits Day High with 9.64% Surge in Stock Price
Agios Pharmaceuticals, Inc. saw a notable increase in stock performance on September 30, 2025, reaching an intraday high. While the company has outperformed the S&P 500 in the short term, it faces long-term challenges, including declining net sales and low profitability metrics.
Agios Pharmaceuticals Experiences Revision in Stock Evaluation Amid Market Dynamics
Agios Pharmaceuticals, Inc. has recently revised its evaluation amid market dynamics, with its stock price reflecting notable volatility over the past year. Technical indicators present a mixed outlook, while the company has shown short-term resilience compared to the S&P 500, although it has struggled over longer periods.
Is Agios Pharmaceuticals, Inc. technically bullish or bearish?
As of September 2, 2025, Agios Pharmaceuticals has a mildly bullish technical trend, supported by strong weekly indicators but mixed monthly signals, while outperforming the S&P 500 recently but underperforming over longer periods.
Is Agios Pharmaceuticals, Inc. overvalued or undervalued?
As of August 13, 2025, Agios Pharmaceuticals is considered undervalued with a favorable P/E ratio of 4 and a PEG ratio of 0.01, despite a one-year return of -16.67% compared to the S&P 500's 17.14%, indicating potential for recovery.
Is Agios Pharmaceuticals, Inc. overvalued or undervalued?
As of May 20, 2025, Agios Pharmaceuticals is considered very attractive and undervalued with a P/E ratio of 4 and a PEG ratio of 0.01, showing potential for growth despite recent challenges and outperforming the S&P 500 with an 11.88% return over the last month.
Is Agios Pharmaceuticals, Inc. technically bullish or bearish?
As of June 18, 2025, Agios Pharmaceuticals, Inc. shows a neutral technical trend with mixed signals, indicating a shift from mildly bearish to sideways, while the overall market sentiment remains weak and uncertain.
Who are in the management team of Agios Pharmaceuticals, Inc.?
As of March 2022, the management team of Agios Pharmaceuticals, Inc. includes Dr. David Schenkein (Executive Chairman), Dr. Jacqualyn Fouse (CEO), Dr. David Scadden, and independent directors Paul Clancy, Ian Clark, Kaye Foster, and Maykin Ho. They are responsible for the company's strategic direction and operations.
What does Agios Pharmaceuticals, Inc. do?
Agios Pharmaceuticals, Inc. is a clinical-stage biopharmaceutical company focused on developing therapies for cancer and rare genetic metabolic disorders. As of March 2025, it reported net sales of $9 million and a net loss of $89 million, with a market cap of $2.56 billion.
How big is Agios Pharmaceuticals, Inc.?
As of Jun 18, Agios Pharmaceuticals, Inc. has a market capitalization of $2.56 billion, with net sales of $37.04 million and a net profit of $665.98 million over the latest four quarters.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
